Physician profile
Glenn Turner
NPI 1073656203
$18,315.72
in general payments reported to CMS, 2019-2025
64 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,878 · 2022: $3,675 · 2023: $3,269 · 2024: $3,385 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,613 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,613.07 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,334.64 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,558.01 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,366.06 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $1,112.36 | 2021-2025 | |
| Amgen INC. | $971.04 | 2021-2025 | Aimovig, Uplizna |
| Celgene Corporation | $885.69 | 2021-2025 | Zeposia |
| Pfizer INC. | $813.57 | 2023-2025 | |
| Eisai INC. | $763.25 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $605.46 | 2021-2025 | Ingrezza, Ongentys |
| Upsher-Smith Laboratories LLC | $549.64 | 2021-2023 | |
| Biogen, INC. | $533.81 | 2021-2023 | Tysabri |
| Neurelis, INC. | $527.80 | 2021-2025 | Valtoco |
| Emd Serono, INC. | $466.82 | 2021-2025 | Mavenclad |
| Kyowa Kirin, INC. | $433.13 | 2021-2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $402.25 | 2021-2023 | Ponvory |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.